Invention Grant
- Patent Title: Heterocyclic compound and use thereof
-
Application No.: US16827316Application Date: 2020-03-23
-
Publication No.: US11279713B2Publication Date: 2022-03-22
- Inventor: Masakuni Kori , Toshihiro Imaeda , Shinji Nakamura , Masashi Toyofuku , Eiji Honda , Yasutomi Asano , Osamu Ujikawa , Michiyo Mochizuki
- Applicant: Takeda Pharmaceutical Company Limited
- Applicant Address: JP Osaka
- Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee Address: JP Osaka
- Agency: Finnegan, Henderson Farabow, Garrett & Dunner LLP
- Priority: JPJP2010-179577 20100810
- Main IPC: C07D513/04
- IPC: C07D513/04

Abstract:
Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.
Public/Granted literature
- US20200317692A1 HETEROCYCLIC COMPOUND AND USE THEREOF Public/Granted day:2020-10-08
Information query